Genome Editing in Human iPS Cells to Study and Cure Disease
Human iPS (induced pluripotent stem) cells have the potential to allow us to study diseases in virtually any type of human cell, and develop cell transplantation-based therapies. Our team is developing and improving genome editing technology in iPS cells. We are developing novel isogenic iPS cell-based disease models, and correcting mutations in iPS cells from patients, a critical step in transplantation-based therapies. Our current focus is on diseases affecting cardiomyocytes and hepatocytes. →More
News
2024. 11. 1. Noa Tozawa joins the lab as an Intern!
2024. 10. 4. Lab trip to the Nakatsugawa trout fishing ground.
2024. 10. 1. Hiroto Serita and Ryo Shiraki join the lab as Interns!
2024. 9. 19. Isolation and analysis of >1,000 genome-edited iPS cell clones in collaboration with Yamaha Mortor is out in bioRxiv.
2024. 9. 2. Daisuke Matsumoto joins the lab as a Staff Scientist!
2024. 8. 19. Tomoya Okada joins the lab as a Summer Intern!
2024. 5. 13. Our paper on effects of fusion of Cas9 and histone variants to inhibit NHEJ is out in PLOS ONE.
2024. 4. 1. Kai Zhang joins the lab as a graduate student!
2024. 3. 29. A staff scientist position is still open.
2024. 3. 17. Lab ski trip to Togari Onsen
2024. 3. 11. Lanyu Huang and Minato Maeda win the best presentation award in the Institutional poster presentation competition.
2024. 1. 24. We hire a staff scientist.
2023. 12. 27. Kayoko Shinozaki is awarded the Belle Foundation Fellowship!!
Upcoming
2024. 12. 4-7. CSHL Meeting, Neurodegenerative Diseases: Biology & Therapeutics (Yuga Yasuda's Poster Presentation)
2024. 12. 5. Seminar at Ome Nursing School
2025. 3. 20-22. Congress of the Japanese Society for Regenerative Medicine @ Pacifico Yokohama